Table 1 Baseline patient and tumor characteristics (n = 431).
Characteristics | Adjuvant PF Chemotherapy (n = 152) | Observation (n = 279) | p value |
|---|---|---|---|
Sex | 0.26 | ||
Male | 127 (83.6) | 219 (78.5) | |
Female | 25 (16.4) | 60 (21.5) | |
Age, median (IQR) | 46 (38.8–53) | 50 (41–58) | 0.001 |
Age, mean (SD) | 45.8 (10.8) | 49.6 (12.7) | 0.002 |
Histology | 0.04 | ||
Lymphoepithelial / undifferentiated / NOS carcinoma | 38 (25.0) | 42 (15.1) | |
Squamous cell carcinoma, keratinizing or NOS | 3 (2.0) | 7 (2.5) | |
Squamous cell carcinoma, non-keratinizing | 111 (73.0) | 230 (82.4) | |
Clinical T classification | 0.81 | ||
T1 | 51 (33.6) | 106 (38.0) | |
T2 | 30 (19.7) | 51 (18.3) | |
T3 | 34 (22.4) | 55 (19.7) | |
T4 | 37 (24.3) | 67 (24.0) | |
Clinical N classification | 0.24 | ||
N3a | 42 (27.6) | 94 (33.7) | |
N3b | 110 (72.4) | 185 (66.3) | |
Radiotherapy dose (Gray), median (IQR) | 70 (70–72) | 72 (70–72) | 0.23 |
Radiotherapy fractions, median (IQR) | 35 (35–37) | 36 (35–37) | 0.83 |
Median (IQR) follow-up, years | 4.7 (3.7–6.6) | 4.0 (2.6–6.6) | 0.11 |
